Six reverse splits totaling a cumulative 1-for-56,250 ratio since 2023 have failed to outrun a convertible-note cycle that gives unnamed lenders control over how large the float becomes.
Three separate dilution mechanisms — a discounted preferred redemption, reset warrants, and a variable-rate convertible note — can each independently exceed Generation Income Properties' 2.58-million-share public float, and no major data service reflects any of them.
Two variable-priced dilution mechanisms — a Lincoln Park equity line and a set of 22%-discount convertible notes — sit behind approximately 5.6 million shares of identified overhang against a float estimated at just 4.4 million.
With a variable-rate financing ban expiring in weeks and only $6.4 million in cash, the Israeli oncology company's next supply event is a matter of when, not if.
With 7.5 million warrants carrying a demonstrated repricing history and a baby shelf nearly exhausted, the tonneau-cover and clean-energy company's pending overhang equals 100% of its current public float.
A Form F-1 filed July 10 would release 2.28 million restricted shares bought at $0.25 into a free-trading pool of just 3.83 million — and 1.48 million full-ratchet warrants sit behind them.
A free premarket dispatch from the ShareStructure News desk — the movers that matter, with the dilution read most traders miss.
Free · No spam · Unsubscribe anytime
Two reverse splits compressed 24.6 million shares into 1.6 million in four months, and shareholders have already approved a third at up to 1-for-100 — executable at the board's discretion through mid-2027.
Three registered equity events in 60 days and a 7-million-share warrant block frame the structural reality of this freshly listed Cayman metals holding company.
Non-affiliate Class A shares jumped 131% between late May and late July 2026, but only 3.6 million of the roughly 27.7 million new free-trading shares trace to a documented offering.
A freshly signed at-the-market facility gives the China-based holding company capacity to issue more shares than currently trade — atop a 95% share-count increase in the past twelve months.
A serial warrant-inducement cycle has quadrupled Creative Medical Technology's outstanding warrants in 21 months while a pending stockholder vote could lift authorized shares from 25 million to 100 million.
A single institutional investor holds pre-funded warrants and investment options that, if fully exercised and sold, would add roughly 547% to the company's current float.
An S-1/A filing reveals a massive pre-funded warrant overhang that dwarfs the company's outstanding share count by more than tenfold.